BofA: Investors pour into bonds, pull back from crypto
In a stark reflection of the tumultuous market conditions, Zynex Inc. (NASDAQ:ZYXI) has seen its stock price plummet to $1.85, near its 52-week low of $1.93, marking a dramatic fall from its peak of $12.19. The medical technology company, which specializes in non-invasive pain management devices, has faced a harrowing year, with its stock value declining nearly 80% over the past year. Despite the challenging market conditions, management has been actively buying back shares, and the company maintains strong liquidity with a current ratio of 3.46. Investors have been wary as the company grapples with competitive pressures and a challenging healthcare market, leading to a significant reevaluation of Zynex’s growth prospects. The current price level represents a critical juncture for the company, as it strives to regain investor confidence and stabilize its financial footing in the face of persistent market headwinds. According to InvestingPro analysis, the stock appears undervalued at current levels, with 12 additional exclusive insights available to subscribers.
In other recent news, Zynex Inc. reported its financial results for the first quarter of 2025, revealing a significant miss on earnings and revenue expectations. The company posted an earnings per share (EPS) of -$0.33, falling short of the forecasted $0.06, and reported revenue of $26.58 million, well below the anticipated $53.47 million. Zynex’s revenue decreased notably from $46.5 million in the same quarter of the previous year. As part of its strategic initiatives, the company is developing a new pulse oximeter with innovative technology, which is expected to generate revenue in 2026. The company is also undergoing staff reductions and restructuring efforts to improve financial performance. Challenges with TRICARE reimbursements remain unresolved, impacting the company’s revenue stream. Looking forward, Zynex has set a revenue estimate of $27 million for the second quarter of 2025, with an expected EPS loss of $0.20 per share. Analysts from RBC and H.C. Wainwright have shown interest in the company’s future plans and financial health, particularly concerning TRICARE reimbursements and the launch of the NICO Pulse Oximeter.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.